These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17132715)

  • 21. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
    Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
    Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.
    Crow AR; Suppa SJ; Chen X; Mott PJ; Lazarus AH
    Blood; 2011 Dec; 118(24):6403-6. PubMed ID: 22001393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet antibody-induced thrombocytopenia does not correlate with megakaryocyte abnormalities in murine immune thrombocytopenia.
    Guo L; Kapur R; Aslam R; Hunt K; Hou Y; Zufferey A; Speck ER; Rondina MT; Lazarus AH; Ni H; Semple JW
    Scand J Immunol; 2018 Jul; 88(1):e12678. PubMed ID: 29855061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin-induced thrombocytopenia and other immune thrombocytopenias: lessons from mouse models.
    McKenzie SE; Reilly MP
    Semin Thromb Hemost; 2004 Oct; 30(5):559-68. PubMed ID: 15497098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.
    Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR
    Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG.
    Liang SX; Pinkevych M; Khachigian LM; Parish CR; Davenport MP; Chong BH
    Blood; 2010 Sep; 116(11):1958-60. PubMed ID: 20566900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura.
    Bussel JB
    Clin Immunol Immunopathol; 1989 Nov; 53(2 Pt 2):S147-55. PubMed ID: 2477185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP).
    Neschadim A; Branch DR
    Curr Protoc Immunol; 2016 Apr; 113():15.30.1-15.30.13. PubMed ID: 27038460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intravenous immunoglobulin on inhibition of fibrinogen binding to platelets by sera from patients with immune thrombocytopenia.
    Kamiyama M; Yoshimura Y; Chen K; Arkel YS
    Am J Hematol; 1993 Oct; 44(2):77-84. PubMed ID: 8266923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.
    Blanchette V; Carcao M
    Transfus Sci; 1998 Sep; 19(3):279-88. PubMed ID: 10351140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of panaxadiol saponins on megakaryocytic maturation and immune function in a mouse model of immune thrombocytopenia.
    Lin X; Yin L; Gao R; Liu Q; Xu W; Jiang X; Chong BH
    Exp Hematol; 2015 May; 43(5):364-373. PubMed ID: 25578384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia.
    Aslam R; Hu Y; Gebremeskel S; Segel GB; Speck ER; Guo L; Kim M; Ni H; Freedman J; Semple JW
    Blood; 2012 Sep; 120(10):2127-32. PubMed ID: 22760780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of maternally administered immunoglobulin on platelet counts of neonates born to mothers with autoimmune thrombocytopenia: re-evaluation.
    Bessho T; Ida A; Minagawa K; Koyama K
    Clin Exp Obstet Gynecol; 1997; 24(2):53-7. PubMed ID: 9342461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.
    Bazin R; Lemieux R; Tremblay T; St-Amour I
    Br J Haematol; 2004 Oct; 127(1):90-6. PubMed ID: 15384982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.
    Lewis BJB; Leontyev D; Neschadim A; Blacquiere M; Branch DR
    Clin Exp Immunol; 2018 Sep; 193(3):293-301. PubMed ID: 29704458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia.
    Li J; van der Wal DE; Zhu L; Vadasz B; Simpson EK; Li C; Webster ML; Zhu G; Lang S; Chen P; Zeng Q; Ni H
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):50-8. PubMed ID: 23082940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
    Crow AR; Song S; Siragam V; Lazarus AH
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura.
    van der Lugt NM; van Kampen A; Walther FJ; Brand A; Lopriore E
    Vox Sang; 2013 Oct; 105(3):236-43. PubMed ID: 23782272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial.
    Benesch M; Kerbl R; Lackner H; Berghold A; Schwinger W; Triebl-Roth K; Urban C
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):797-800. PubMed ID: 14528103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.